Janssen’s Sirturo: TB Milestone Awaits After Advisory Committee Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
Important safety questions remain for what could be the first new tuberculosis drug in 40 years, and there was a lack of efficacy in the key subgroup of black patients.
You may also be interested in...
FDA Defends ‘Paradoxical’ Approval Of J&J’s TB Drug Sirturo In NEJM
Imbalance of deaths for bedaquiline patients despite efficacy on surrogate marker in Phase II study supporting accelerated approval is still unexplained with longer-term data. But with efficacy also still looking good, FDA defends approval for select population with high unmet need.
Emerging Markets Focused J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.
J&J’s Sirturo Approval Tied To Expansive Post-Marketing Study Program
The first drug approved for multi-drug resistant tuberculosis, Sirturo obtained accelerated approval based on data from two Phase II studies, but has a troubling safety database, including 10 deaths in the treatment arm of its Phase II program.